The anti-inflammatory effects of oral-formulated tacrolimus in mice with experimental autoimmune encephalomyelitis

Myung Jin Kim, Jung Joon Sung, Seung Hyun Kim, Jeong Min Kim, Gye Sun Jeon, Seog Kyun Mun, Suk Won Ahn

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is a T-lymphocyte-mediated autoimmune disease that is characterized by inflammation in the central nervous system (CNS). Although many disease-modifying therapies (DMTs) are presumed effective in patients with MS, studies on the efficacy and safety of DMTs for preventing MS relapse are limited. Therefore, we tested the immunosuppressive anti-inflammatory effects of oral-formulated tacrolimus (FK506) on MS in a mouse model of experimental autoimmune encephalomyelitis (EAE). The mice were randomly divided into 3 experimental groups: an untreated EAE group, a low-dose tacrolimus-treated EAE group, and a high-dose tacrolimus-treated EAE group. After autoimmunization of the EAE mice with myelin oligodendrocyte glycoprotein, symptom severity scores, immunohistochemistry of the myelination of the spinal cord, and western blotting were used to evaluate the EAE mice. After the autoimmunization, the symptom scores of each EAE group significantly differed at times. The group treated with the larger tacrolimus dose had the lowest symptom scores. The tacrolimus-treated EAE groups exhibited less demyelination and inflammation and weak immunoreactivity for all of the immunization biomarkers. Our results revealed that oral-formulated tacrolimus inhibited the autoimmunization in MS pathogenesis by inactivating inflammatory cells.

Original languageEnglish
Pages (from-to)1502-1507
Number of pages6
JournalJournal of Korean Medical Science
Volume32
Issue number9
DOIs
StatePublished - 2017 Sep 1

Fingerprint

Autoimmune Experimental Encephalomyelitis
Tacrolimus
Anti-Inflammatory Agents
Multiple Sclerosis
Inflammation
Demyelinating Diseases
Immunosuppressive Agents
Autoimmune Diseases
Immunization
Spinal Cord
Central Nervous System
Biomarkers
Western Blotting
Immunohistochemistry
T-Lymphocytes
Safety
Recurrence
Therapeutics

Keywords

  • EAE
  • Experimental autoimmune encephalomyelitis
  • FK506
  • Multiple sclerosis
  • Neuromyelitis optica
  • Tacrolimus

Cite this

Kim, Myung Jin ; Sung, Jung Joon ; Kim, Seung Hyun ; Kim, Jeong Min ; Jeon, Gye Sun ; Mun, Seog Kyun ; Ahn, Suk Won. / The anti-inflammatory effects of oral-formulated tacrolimus in mice with experimental autoimmune encephalomyelitis. In: Journal of Korean Medical Science. 2017 ; Vol. 32, No. 9. pp. 1502-1507.
@article{625201180de44496ac5aeda85d0dd018,
title = "The anti-inflammatory effects of oral-formulated tacrolimus in mice with experimental autoimmune encephalomyelitis",
abstract = "Multiple sclerosis (MS) is a T-lymphocyte-mediated autoimmune disease that is characterized by inflammation in the central nervous system (CNS). Although many disease-modifying therapies (DMTs) are presumed effective in patients with MS, studies on the efficacy and safety of DMTs for preventing MS relapse are limited. Therefore, we tested the immunosuppressive anti-inflammatory effects of oral-formulated tacrolimus (FK506) on MS in a mouse model of experimental autoimmune encephalomyelitis (EAE). The mice were randomly divided into 3 experimental groups: an untreated EAE group, a low-dose tacrolimus-treated EAE group, and a high-dose tacrolimus-treated EAE group. After autoimmunization of the EAE mice with myelin oligodendrocyte glycoprotein, symptom severity scores, immunohistochemistry of the myelination of the spinal cord, and western blotting were used to evaluate the EAE mice. After the autoimmunization, the symptom scores of each EAE group significantly differed at times. The group treated with the larger tacrolimus dose had the lowest symptom scores. The tacrolimus-treated EAE groups exhibited less demyelination and inflammation and weak immunoreactivity for all of the immunization biomarkers. Our results revealed that oral-formulated tacrolimus inhibited the autoimmunization in MS pathogenesis by inactivating inflammatory cells.",
keywords = "EAE, Experimental autoimmune encephalomyelitis, FK506, Multiple sclerosis, Neuromyelitis optica, Tacrolimus",
author = "Kim, {Myung Jin} and Sung, {Jung Joon} and Kim, {Seung Hyun} and Kim, {Jeong Min} and Jeon, {Gye Sun} and Mun, {Seog Kyun} and Ahn, {Suk Won}",
year = "2017",
month = "9",
day = "1",
doi = "10.3346/jkms.2017.32.9.1502",
language = "English",
volume = "32",
pages = "1502--1507",
journal = "Journal of Korean medical science",
issn = "1011-8934",
number = "9",

}

The anti-inflammatory effects of oral-formulated tacrolimus in mice with experimental autoimmune encephalomyelitis. / Kim, Myung Jin; Sung, Jung Joon; Kim, Seung Hyun; Kim, Jeong Min; Jeon, Gye Sun; Mun, Seog Kyun; Ahn, Suk Won.

In: Journal of Korean Medical Science, Vol. 32, No. 9, 01.09.2017, p. 1502-1507.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The anti-inflammatory effects of oral-formulated tacrolimus in mice with experimental autoimmune encephalomyelitis

AU - Kim, Myung Jin

AU - Sung, Jung Joon

AU - Kim, Seung Hyun

AU - Kim, Jeong Min

AU - Jeon, Gye Sun

AU - Mun, Seog Kyun

AU - Ahn, Suk Won

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Multiple sclerosis (MS) is a T-lymphocyte-mediated autoimmune disease that is characterized by inflammation in the central nervous system (CNS). Although many disease-modifying therapies (DMTs) are presumed effective in patients with MS, studies on the efficacy and safety of DMTs for preventing MS relapse are limited. Therefore, we tested the immunosuppressive anti-inflammatory effects of oral-formulated tacrolimus (FK506) on MS in a mouse model of experimental autoimmune encephalomyelitis (EAE). The mice were randomly divided into 3 experimental groups: an untreated EAE group, a low-dose tacrolimus-treated EAE group, and a high-dose tacrolimus-treated EAE group. After autoimmunization of the EAE mice with myelin oligodendrocyte glycoprotein, symptom severity scores, immunohistochemistry of the myelination of the spinal cord, and western blotting were used to evaluate the EAE mice. After the autoimmunization, the symptom scores of each EAE group significantly differed at times. The group treated with the larger tacrolimus dose had the lowest symptom scores. The tacrolimus-treated EAE groups exhibited less demyelination and inflammation and weak immunoreactivity for all of the immunization biomarkers. Our results revealed that oral-formulated tacrolimus inhibited the autoimmunization in MS pathogenesis by inactivating inflammatory cells.

AB - Multiple sclerosis (MS) is a T-lymphocyte-mediated autoimmune disease that is characterized by inflammation in the central nervous system (CNS). Although many disease-modifying therapies (DMTs) are presumed effective in patients with MS, studies on the efficacy and safety of DMTs for preventing MS relapse are limited. Therefore, we tested the immunosuppressive anti-inflammatory effects of oral-formulated tacrolimus (FK506) on MS in a mouse model of experimental autoimmune encephalomyelitis (EAE). The mice were randomly divided into 3 experimental groups: an untreated EAE group, a low-dose tacrolimus-treated EAE group, and a high-dose tacrolimus-treated EAE group. After autoimmunization of the EAE mice with myelin oligodendrocyte glycoprotein, symptom severity scores, immunohistochemistry of the myelination of the spinal cord, and western blotting were used to evaluate the EAE mice. After the autoimmunization, the symptom scores of each EAE group significantly differed at times. The group treated with the larger tacrolimus dose had the lowest symptom scores. The tacrolimus-treated EAE groups exhibited less demyelination and inflammation and weak immunoreactivity for all of the immunization biomarkers. Our results revealed that oral-formulated tacrolimus inhibited the autoimmunization in MS pathogenesis by inactivating inflammatory cells.

KW - EAE

KW - Experimental autoimmune encephalomyelitis

KW - FK506

KW - Multiple sclerosis

KW - Neuromyelitis optica

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=85026779399&partnerID=8YFLogxK

U2 - 10.3346/jkms.2017.32.9.1502

DO - 10.3346/jkms.2017.32.9.1502

M3 - Article

C2 - 28776347

AN - SCOPUS:85026779399

VL - 32

SP - 1502

EP - 1507

JO - Journal of Korean medical science

JF - Journal of Korean medical science

SN - 1011-8934

IS - 9

ER -